Global Basal Cell Carcinoma Treatment Market Size, Status and Forecast 2019-2025

Basal cell carcinoma (BCC) is the most common type of skin cancer. It’s also the most commonly diagnosed cancer in the United States. Every year, millions of people learn that they have BCC.

Basal cell carcinoma that is superficial and doesn't extend very far into the skin may be treated with creams or ointments. Surgical options are Electrodesiccation and curettage (ED&C), Topical Treatment, Freezing and Mohs Surgery. Drugs options, imiquimod (Aldara) and fluorouracil (Efudex, Fluoroplex, others) are used for several weeks to treat such low-risk basal cell carcinomas. Basal cell carcinoma that spreads to other areas of the body (metastasizes) may be treated with vismodegib (Erivedge) or sonidegib (Odomzo).
The classification of Basal Cell Carcinoma Treatment includes Topical Treatment, Hedgehog Pathway Inhibitor Therapy, Mohs Surgery, Other Surgeries and Other Treatments, and the proportion of Topical Treatment in 2018 is about 30.4%. Basal Cell Carcinoma Treatment is widely used in Hospitals, Specialty Clinics and other field. The most proportion of Basal Cell Carcinoma Treatment is Hospitals, and the sales proportion in 2018 is 53.2%. Market competition is intense. Roche, Sun Pharmaceuticals, Bausch Health Companies, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers.
In 2018, the global Basal Cell Carcinoma Treatment market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Basal Cell Carcinoma Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Basal Cell Carcinoma Treatment development in USA..

The key players covered in this study

Sun Pharmaceuticals
Bausch Health Companies
Taro Pharmaceuticals

Market segment by Type, the product can be split into

Topical Treatment
Hedgehog Pathway Inhibitor Therapy
Mohs Surgery
Other Surgeries
Other Treatments

Mohs Surgery accounts for a larger share of the market, about 31% in 2018.

Market segment by Application, split into

Specialty Clinics

The largest application is in hospital, which accounted for 53.15% in 2018.

Market segment by Regions/Countries, this report covers


The study objectives of this report are:

To analyze global Basal Cell Carcinoma Treatment status, future forecast, growth opportunity, key market and key players.
To present the Basal Cell Carcinoma Treatment development in USA..
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Basal Cell Carcinoma Treatment are as follows:
History Year: 2014-2018

Base Year:


Estimated Year:

Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Frequently Asked Questions

This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.

  • By product type
  • By End User/Applications
  • By Technology
  • By Region

The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.

Please Select a Format

market Reports market Reports